EASL 2020

infohep news

• Experimental treatments for NASH/NAFLD

  Cotadutide improves metabolic and liver biomarkers in people with NAFLD and diabetes

  Liz Highleyman / 26 October 2020

  Cotadutide, an experimental therapy that alters glucose and lipid metabolism, led to weight loss and improvements in metabolic, cardiovascular and liver fibrosis biomarkers in overweight people with diabetes and fatty liver disease, but ...

• Experimental treatments for NASH/NAFLD

  Experimental NASH treatments: Gilead candidates miss primary endpoint but show some benefits

  Liz Highleyman / 20 October 2020

  Combinations of experimental drugs for non-alcoholic steatohepatitis (NASH) failed to meet a study's primary endpoint by significantly improving liver fibrosis without worsening NASH, but one combination in particular – firsocostat plus ...

• Hepatocellular carcinoma (HCC)

  Models can help predict liver cancer in people cured of hepatitis C

  Liz Highleyman / 17 September 2020

  Three new methods using readily available clinical parameters can help predict who will develop hepatocellular carcinoma (HCC) after achieving sustained virological response to hepatitis C treatment, according to studies presented at the recent 2020 Digital ...

• Coronavirus

  International registries provide more information about COVID-19 and liver disease

  Liz Highleyman / 17 September 2020

  People with advanced liver cirrhosis are more likely to develop severe COVID-19 complications and to die from it, but those who have received liver transplants do not appear to be at greater ...

• Experimental treatments for NASH/NAFLD

  Aldafermin reduces liver fat in phase 2 study

  Keith Alcorn / 14 September 2020

  Aldafermin significantly reduced liver fat content and liver damage in a phase 2 study of a 24-week treatment course, Dr Stephen Harrison, Visiting Professor of Hepatology at the University of Oxford, told ...

• NAFLD

  Fatty liver disease affects one in four in Europe, study estimates

  Keith Alcorn / 07 September 2020

  Non-alcoholic fatty liver disease affects one in four people in the general population in Europe and just over one in twenty people have advanced liver fibrosis, a meta-analysis of 33 studies from ...

• Antiviral therapy

  Stopping antivirals may offer a chance for a hepatitis B cure

  Liz Highleyman / 06 September 2020

  Discontinuation of long-term nucleoside/nucleotide antiviral treatment for hepatitis B can allow some people to achieve a cure, according to a pair of presentations last week at the 2020 Digital International Liver Congress. This may happen ...

• Treatment for hepatocellular carcinoma

  Immunotherapy combinations show promise for advanced liver cancer

  Liz Highleyman / 02 September 2020

  Three checkpoint inhibitor immunotherapy regimens show promise for people with hepatocellular carcinoma (HCC), the most common type of liver cancer, according to a set of late-breaking presentations last week at the 2020 Digital ...

• New and experimental treatments for hepatitis B

  Gilead immune modulator has modest effect on hepatitis B surface antigen

  Keith Alcorn / 01 September 2020

  Selgantolimod, a toll-like receptor agonist designed to enhance immune responses to hepatitis B virus, showed only modest effects on hepatitis B surface antigen levels in a phase 2 safety and efficacy study presented ...

• Hepatitis delta

  Bulevirtide shows promise as maintenance therapy for hepatitis D

  Liz Highleyman / 30 August 2020

  High-dose bulevirtide (Hepcludex) combined with pegylated interferon alfa-2a (Pegasys) or tenofovir disoproxil fumarate (TDF; Viread) led to suppression of hepatitis delta virus (HDV), according to a presentation this week at the 2020 Digital International ...